TITLE

High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients

AUTHOR(S)
D. Rey; B. Hoen; P. Chavanet; M. P. Schmitt; G. Hoizey; P. Meyer; G. Peytavin; B. Spire; C. Allavena; M. Diemer; T. May; J. L. Schmit; M. Duong; V. Calvez; J. M. Lang
PUB. DATE
February 2009
SOURCE
Journal of Antimicrobial Chemotherapy (JAC);Feb2009, Vol. 63 Issue 2, p380
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
: Background The combination of one non-nucleoside reverse transcriptase inhibitor (NNRTI) with two nucleoside reverse transcriptase inhibitors is a validated first-line antiretroviral (ARV) therapy. The once-daily combination of lamivudine, tenofovirDF and nevirapine has not been evaluated in a clinical trial. : Methods Randomized, open-label, multicentre, non-inferiority trial comparing lamivudine, tenofovirDF and nevirapine once daily (Group 2) with zidovudine/lamivudine and nevirapine twice daily (Group 1), in naive HIV-1-infected patients with a CD4 count <350/mm3. We planned to enrol 250 patients. : Results As of May 2006, 71 patients had been enrolled (35 in Group 1 and 36 in Group 2) and an unplanned interim analysis was done. The groups were comparable at baseline: median CD4 count was 195 and 191/mm3 and median plasma viral load was 4.9 log10 and 5.01 log10, respectively, in Groups 1 and 2. Eight early non-responses (22.2%) were observed, all in Group 2, while two later viral rebounds occurred. Resistance genotypes for the nine Group 2 failing patients showed the mutations M184V/I (n = 3), K65R (n = 6), one or more NNRTI resistance mutations in all cases. At baseline, the nine Group 2 patients who failed had higher median plasma viral load (5.4 log10) and lower median CD4 count (110/mm3) than the other Group 2 patients (4.7 log10, P = 0.002 and 223/mm3, P = 0.004). Nevirapine trough concentrations were not different between the two groups, nor between patients with full viral suppression or those who failed in Group 2. Due to slow recruitment, and those results, the steering committee decided to stop the trial at 12 months. : Conclusions In ARV-naive HIV-1-infected patients, the once-daily lamivudine, tenofovirDF and nevirapine regimen resulted in a high rate of early virological failures. The reasons for the failures remain unclear.
ACCESSION #
36092377

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics